Alphamab Oncology released its monthly return for March 2026, showing no changes in either authorised or issued share capital and affirming that its public float continues to exceed the 25% minimum required by Hong Kong listing rules.

Authorised and Issued Capital • Authorised share capital stayed at 25.10 billion ordinary shares with a par value of USD 0.000002, equivalent to USD 50,200. • Issued shares (excluding treasury stock) closed the month at 968.57 million, while treasury shares were unchanged at 5.72 million. Total issued shares therefore remain 974.29 million, the same as at end-February.

Share Option Activity • No new shares were issued and no treasury shares were transferred during March from the three in-place option schemes. • Outstanding options totalled 15.18 million, after 0.50 million options lapsed under the Post-IPO Share Option Plan. • Shares that could still be issued upon exercise of existing options stand at 6.08 million. • A further 95.35 million shares remain available for future grants under the refreshed scheme mandate approved on 12 June 2024.

Share Award Scheme • The restricted share award scheme recorded no share issuances or transfers in March.

Liquidity and Compliance • Alphamab Oncology confirmed that it met the Main Board’s minimum public float threshold of 25% as at 31 March 2026. • No funds were raised from option exercises during the month.

Overall, the company’s capital structure and share count were unchanged in March 2026, with ample headroom for future equity-based incentives and full compliance with Hong Kong Stock Exchange public float requirements.